Daily Stock List
AgriMarine Holdings, Inc. (FSH.V)
Vantage Wire reported previously on AgriMarine Holdings, Inc. (FSH.V), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
AgriMarine Holdings, Inc. is an aquaculture technology company that lists on the TSX Venture Exchange. The Company engages in the development, commercialization and licensing of proprietary floating solid-wall closed containment tank systems for salmon and finfish farming. AgriMarine Holdings has their headquarters in Vancouver, British Columbia.
The Company's clean technology is demonstrating economic and sustainability advantages in the Company's own farms in Canada and China, as well as commercial scalability for hatchery and full grow-out applications. The AgriMarine System™ creates an optimal fish-rearing environment, addresses sustainability issues in finfish aquaculture and is applicable globally in a variety of water bodies and climates.
AgriMarine Holdings holds four subsidiaries directly and indirectly. AgriMarine Industries, Inc. oversees operations and business development opportunities in Canada. Benxi AgriMarine Industries, Inc. was established as a Wholly Foreign Owned Enterprise (WFOE) in Benxi, Liaoning Province, China for the commercial application of their technology for rearing trout and salmon.
AgriMarine Aquaculture Technologies (Beijing) Co. Ltd. was established as a Foreign-Invested Commercial Enterprise Entity (FICE) to provide local support to distributors and expand sales of their fish products in China. Furthermore, AgriMarine Holdings has a 50 percent ownership in AgriMarine Norway AS. In addition, AgriMarine Holdings recently established a wholly owned subsidiary based in Hong Kong under the name AgriMarine (Asia) Limited, to pursue regional business opportunities.
In late March of this year, AgriMarine Holdings reported the first commercial harvest at the Company's Canadian demonstration site at Middle Bay on Vancouver Island, British Columbia. They previously announced damage to their floating, solid-wall containment tank incurred during a hurricane-grade windstorm that hit Vancouver Island earlier in March 2012. After an initial assessment of the damage, they harvested their first crop of Chinook salmon. They subsequently began the process of raising the tank for insurance evaluation and repair. The Company proceeded with the demonstration project, which is partly funded by Sustainable Development Technology Canada (SDTC).
Last week, AgriMarine Holdings announced the appointments of Ms. Lily Gao as Chief Operating Officer (China) and Mr. Josh McKibben (Hong Kong) as General Manager of Farm Operations, effective immediately. As a qualified lawyer in China, Ms. Gao has extensive experience working for foreign-based, international law firms in the areas of investment, M&As, commercial transactions, business structuring and labor issues. Mr. McKibben brings significant practical aquaculture experience to AgriMarine, having worked in the salmon farming industry for over 12 years. He managed marine aquaculture projects in Australia, Hong Kong and Panama.
AgriMarine Holdings, Inc. (FSH.V), closed Thursday at $0.16, even with yesterday’s close.
BioCurex, Inc. (BOCX)
Bull in Advantage, Dynamic Wealth Report, OTCPicks, and Mega Stock Picks reported earlier on BioCurex, Inc. (BOCX), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
BioCurex, Inc. is a development stage biotechnology company developing products based on patented and proprietary technology in the area of cancer diagnostics. The technology identifies a universal cancer marker known as RECAF. Patents have been granted in the United States, Europe, Australia and China. They are pending in other major global markets. BioCurex lists on the OTC Bulletin Board. The Company has their corporate headquarters in Richmond, British Columbia.
The Company is commercializing their technology via licensing arrangements with companies that develop and market diagnostic tests for the large automated clinical laboratory setting, through development and marketing of non-automated clinical laboratory tests, through development of rapid, point-of-care test formats, and through marketing of their OncoPet RECAF test for cancer in companion animals.
RECAF is a molecule that is present on cancer cells but not detected in significant levels on healthy cells or benign tumor cells. It is the receptor for alpha-fetoprotein. It has classification as an oncofetal antigen due to its presence on both fetal and malignant tissues. This characteristic makes RECAF a more accurate indicator of cancer than most current tumor markers.
BioCurex's business model is to develop internally their RECAF cancer diagnostic platform to the stage where individual applications can be partnered or licensed in strategic relationships for regulatory approval and commercialization. The Company's goal is to receive cash from licensing fees, milestone payments, and royalties from such partnerships that support continued development of their cancer diagnostic portfolio.
BioCurex has signed licensing agreements for their cancer detection blood tests with Abbott Laboratories and with Inverness Medical Innovations. In the veterinarian market, the Company's goal is to commercialize their technology via their subsidiary, OncoPet Diagnostics, and with distributors in North America, Europe and elsewhere.
BioCurex recently announced two distribution agreements with Butler Schein Animal Health and Animal Health International, two of the largest animal health companies, for the commercial launch of their RECAF blood test for cancer in dogs. The Company is managing this launch through their wholly owned subsidiary, OncoPet Diagnostics.
BioCurex, Inc. (BOCX), closed Wednesday's trading session at $0.007, down 4.05%, on 250 volume. The average volume for the last 60 days is 260,222. The 52-week low/high is $0.0071/$0.05.
CardioGenics Holdings, Inc. (CGNH)
Daily Markets, FeedBlitz, and M2 Communications reported previously on CardioGenics Holdings, Inc. (CGNH), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
CardioGenics Holdings, Inc. is a development-stage company that engages in the development and commercialization of diagnostic test products to the in vitro diagnostics (IVD) testing market. The Company was formerly known as Jag Media Holdings, Inc. They changed their name to CardioGenics Holdings, Inc. in October of 2009. The Company's shares trade on the OTC Bulletin Board. Founded in 1997 as a biotechnology company, CardioGenics Holdings is based in Mississauga, Ontario.
The Company offers the QL care analyzer, a point-of-care immunoassay analyzer; a series of immunoassay tests to detect cardiac markers; and paramagnetic beads, a proprietary method for silver coating paramagnetic microspheres, which improves instrument sensitivity to light. CardioGenics' immunoassay tests include troponin I, plasminogen activator inhibitor type-1, heart failure risk stratification, and heart failure genomics risk.
At the heart of CardioGenics' Platform is a core technology for improving testing sensitivity to Point of Care (POC) products. The Company has harnessed their core technology to build a compact POC analyzer that employs the most sensitive detection technology, chemiluminescence (CL). They have developed a novel, proprietary and patent-protected method for controlling the delivery of compounds to a chemical reaction, therefore automating their trigger.
The delivery, release and activity of chemical compounds in a chemical reaction are controlled by a method that employs an electronic signal. When applied to a chemiluminescent reaction, release of the trigger chemical compound initiates the chemical reaction and therefore light generation. The result is a highly sensitive testing platform. This technology is deployed in CardioGenics' POC platform, allowing a much-simplified mechanical design.
The QL Care Analyzer represents a shift in the design of POC analyzers. The QLCA is a small, portable, stand-alone and completely automated POC immunoanalyzer. The QLCA has successfully miniaturized lab test technology, and combined it with a simplified mechanical design and proprietary triggering mechanism. The QLCA uses a pre-loaded disposable test cartridge. A non-metered whole blood sample is added to the cartridge to obtain a test result, printed and archived, in 15 minutes. The QLCA employs chemical light generation or chemiluminescence (CL), the same technology used in medical labs.
CardioGenics Holdings, Inc. (CGNH), closed Thursday's trading session at $0.22, down 12.80%, on 3,325 volume with 6 trades. The average volume for the last 60 days is 5,952. The 52-week low/high is $0.16/$0.79.
International Stem Cell Corp. (ISCO)
UndiscoveredEquities and SmarTrend Newsletters reported this month on International Stem Cell Corp. (ISCO), and we highlight the Company, here at the QualityStocks Daily Newsletter.
Trading on the OTCBB, International Stem Cell Corp. (ISCO) focuses on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The Company's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). ISCO also produces and markets specialized cells and growth media for therapeutic research globally by way of their subsidiary Lifeline Cell Technology, and cell-based skin care products through their subsidiary Lifeline Skin Care. ISCO is based in Carlsbad, California.
Stem cells are a class of undifferentiated cells with the potential to develop into a diverse range of specialized cell types in the body. The four most commonly used and described classes of stem cells are "embryonic stem cells" (embryonic SCs), "induced pluripotent stem cells" (iPS), "adult stem cells" (adult SCs) and "parthenogenetic stem cells" (hpSCs). The hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. The Company's scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation.
The hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. The Company's scientists are focusing on using hpSCs to treat severe diseases of the eye, the nervous system and the liver where cell therapy has been proven clinically yet is limited by the availability of safe immune-matched human cells. ISCO has filed their own patent applications covering specific pluripotent hpSC lines and methods to produce new hpSC lines for research, therapeutic and commercial uses.
Earlier this month, ISCO announced that they have developed new technologies to commercialize the use of human parthenogenetic stem cells (hpSC) to treat human diseases. The methods announced this month are capable of producing populations of stem cells and their therapeutically valuable derivatives not only to a higher level of purity but also at a cost that is approximately several times lower than previously reported techniques.
Last week, ISCO announced financial results for the three months ended March 31, 2012. Consolidated net revenues for the three months ended March 31, 2012 were $1.08 million compared to $1.52 million in the corresponding period a year ago. The year-over-year decrease in revenues is due to fewer sales generated from the Lifeline Skin Care (LSC) direct sales channel, partially offset by higher Lifeline Cell Technology (LCT) sales generated from larger distributors.
International Stem Cell Corp. (ISCO), closed at $0.34, even with yesterday’s close, on 141,342 volume with 33 trades. The average volume for the last 60 days is 161,059. The 52-week low/high is $0.34/$1.15.
Remedent, Inc. (REMI)
FeedBlitz and Stock Guru reported previously on Remedent, Inc. (REMI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Remedent, Inc. specializes in the research, development and manufacturing and the marketing of oral care and cosmetic dental products. The Company serves the professional dental industry with innovative technology for dental veneers. Remedent's mission is to become the worldwide leading Dental Service Provider in the direct to consumer market. The Company's shares trade on the OTCBB. Remedent has their headquarters in Gent, Belgium.
The Company serves consumers and the dental community with unique porcelain veneer, teeth whitening, and sensitivity and oral hygiene products. Remedent manufactures, markets, and distributes their products and concepts to more than 35 countries, directly and through a strategic partnership with Den-Mat Holdings LLC, makers of the porcelain veneer laminates, LUMINEERS.
For Business-to-Business products, Remedent developed and marketed whitening products in combination with the high-speed curing lamp Remecure. Remewhite Formulation+ by GlamSmile was the first available in-office power whitening gel featuring Remedent's proprietary CRM-Technology. Remedent created and sells GlamSmile White Boost through dentists for home use. It is an oxygen-induced whitening system.
The Company's leading smile improvement system, GlamSmile, revolutionizes the traditional one-at-a-time method of applying porcelain dental veneers. GlamSmile involves a proprietary veneer fabrication technique and a patented single-motion veneer placement tray that are both guided by a proprietary computer imaging, design, and digital preview system. The tray delivery system lets dentists expertly seat 10 ultra-thin, custom veneers in less than an hour while preserving tooth structure.
Remedent developed "FirstFit". It features a patent-pending system for the creation and placement of dental crowns and bridges. The FirstFit system requires no temporary placements, creates less mouth trauma, and takes fewer office visits to complete. Remedent distributes their products to more than 55 countries.
For Business-to-Consumer, Remedent started with a B2C approach based on the Smile Consultancy Concept. GlamSmile's Smile Consultancy Program goal is to help consumers to realize their dream of a beautiful smile through consulting by a Smile Coach. While the concept still works with dentists, the complete sales cycle is taken over by Remedent. The Company's approach to market the Smile is predominantly internet based.
Remedent, Inc. (REMI), closed Thursday's session at $0.32, even with yesterday’s close. The average volume for the last 60 days is 5,965. The 52-week low/high is $0.12/$0.50.
StemCells, Inc. (STEM)
Hit and Run Candle Sticks, CRWEFinance, CRWEPicks, BestOtc, DrStockPick, StockHotTips, CRWEWallStreet, PennyToBuck, and PennyOmega reported on StemCells, Inc. (STEM), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
StemCells, Inc. engages in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC® cells (purified human neural stem cells), is currently in development as a potential treatment for a broad range of central nervous system disorders. The StemCells team has a distinguished heritage of scientific achievement in stem cell biology. StemCells has their headquarters in Newark, California.
Recently, StemCells reported results from a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children. The trial results showed preliminary evidence of progressive and durable donor-derived myelination in all four patients transplanted with HuCNS-SC cells. The Company is also conducting a Phase I/II clinical trial in chronic spinal cord injury in Switzerland. They have also received authorization from the FDA to initiate a Phase I/II clinical trial in dry age-related macular degeneration (AMD).
Furthermore, StemCells is pursuing preclinical studies of their HuCNS-SC cells in Alzheimer's disease. The Company also markets stem cell research products, including media and reagents, under the SC Proven® brand.
Last week, StemCells announced completion of the first planned interim safety review of the Company's Phase I/II spinal cord injury clinical trial, which indicated that the surgery, immunosuppression and the cell transplants have been well tolerated. The trial, which is designed to evaluate the safety and preliminary efficacy of the Company's proprietary HuCNS-SC® cells (purified human neural stem cells), represents the first time that neural stem cells have been transplanted as a potential therapeutic agent for spinal cord injury.
The interim data is from the first cohort of patients, all of whom suffered a complete spinal cord injury in which there is no neurological function below the level of the injury. The trial, which is taking place at Balgrist University Hospital, Zurich, Switzerland, is the only ongoing clinical trial evaluating neural stem cell transplantation in spinal cord injury.
Dr. Curt, Professor and Chairman of the Spinal Cord Injury Center at the University of Zurich, and Medical Director of the Paraplegic Center at Balgrist University Hospital, said, "We are very encouraged by the interim safety outcomes for the first cohort. The patients in the trial are being closely monitored and undergo frequent clinical examinations, radiological assessments by MRI and sophisticated electrophysiology testing of spinal cord function. The comprehensive battery of tests provides important safety data and is very reassuring as we progress to the next stage of the trial."
StemCells, Inc. (STEM), closed Thursday's session at $0.74, up 2.78%, on 63,727 volume with 279 trades. The average volume for the last 60 days is 292,087. The 52-week low/high is $0.68/$6.88.
Volta Resources, Inc. (VTR.TO)
We are highlighting Volta Resources, Inc. (VTR.TO), here at the QualityStocks Daily Newsletter.
Volta Resources, Inc. is a mineral exploration company that lists on the Toronto Stock Exchange. The Company is focusing on becoming a leader in the identification, acquisition and exploration of gold properties in West Africa. Currently, Volta Resources is fast tracking their flagship Kiaka Gold Project, located in Burkina Faso, towards a development decision. The Company has their headquarters in Toronto, Ontario.
Volta Resources has a combined resource base of 1,031,000 ounces of gold in the Measured category, 1,987,000 ounces of gold in the Indicated category and 2,332,333 ounces of gold and 724,880,000 lbs. of copper in the Inferred category. Volta Resources is exploring on 9 projects, comprising 29 individual properties over highly prospective greenstone belts located in Burkina Faso and Ghana. All of these properties are located on highly prospective Birimian gold belts, similar to those that have delivered several excellent gold mines in West Africa over the last 15 years.
The Company has multiple first class exploration targets. These include two projects in Burkina Faso with NI43-101 compliant gold resources. In 2012, Volta Resources is focusing primarily on their most advanced projects in Burkina Faso. These include extensive and aggressive drilling campaigns at the Kiaka Gold Project, Gaoua Cu-Au project, Nassara gold prospect and the Titao gold project.
More than 105,000 meters of drilling are planned on these four projects during this year. The resource at Kiaka has recently been significantly enhanced with an updated NI43-101 compliant resource for the Kiaka deposit completed in March 2012. The Kiaka Gold Project is located in south central Burkina Faso, approximately 120 kilometers southeast of the capital Ouagadougou. The closest town is Gogo, approximately 15 kilometres from the provincial capital of Manga. The Kiaka Gold Project lies at the intersection of the northeast striking Tenkodogo greenstone belt and the regionally significant north striking Markoye Fault, in whose proximity some of the larger gold resources discovered in Burkina Faso so far, have been discovered.
The Company will focus on fast tracking the Kiaka Gold Project towards a development decision, aiming to complete a Feasibility Study in Q1, 2013. The recent acquisition of properties around Kiaka has provided Volta Resources with an extensive ground position along the highly prospective Markoye Fault Corridor in an important emerging gold province.
The Kiaka Gold Project's NI-43-101 compliant resources include 90.29 million tonnes @ 1.04 g/t Au for 3,018,000 ounces in the Measured and Indicated categories and 38.52 million tonnes @ 1.00 g/t Au for 1,260,000 ounces in the Inferred category including 34.38 million tonnes @ 1.04 g/t Au for 1,145,969 ounces of gold in the Proven category and 91.70 million tonnes @ 0.93 g/t Au for 2,742,353 ounces of gold in the Probable category.
Volta Resources, Inc. (VTR.TO), closed Thursday's trading session at $0.73, up 5.80%, on 324,250 volume. The 52-week low/high is $0.45/$2.13.
Win Global Markets, Inc. (WGMI)
We are reporting on Win Global Markets, Inc. (WGMI), here at the QualityStocks Daily Newsletter.
Founded in 2001, Win Global Markets, Inc. is a leading provider of online trading of binary options. The Company entered the binary options business in November of 2009. They have been offering online trading of binary options through their wholly owned subsidiary, WGM Services Ltd. The Company formerly went by the name Win Gaming Media, Inc. They changed their name to Win Global Markets, Inc. in October 2011.
Win Global Markets' online binary options trading business is marketed towards customers who are seeking to realize a profit from their trades within a short period. The Company owns proprietary software that enables online trading of binary options. Their customers can trade on a variety of financial assets. These include Stocks, Indices/Futures, Commodities and Foreign Currencies that are quoted on leading financial markets worldwide.
The online trading platform is offered in six different languages through two leading brands. These are www.eztrader.com and www.globaloption.com targeting the worldwide traders' community.
In March of this year, Win Global Markets announced that their wholly owned subsidiary, WGM Services entered into an agreement with NASDAQ OMX for the distribution of NASDAQ OMX price quotes of U.S. markets and Nordic exchanges in Stockholm, Copenhagen and Helsinki. With the agreement entered, certain NASDAQ OMX price quotes will be featured on WGM's two leading Internet brands: EZTrader.com and GlobalOption.com. WGM is the only online binary option trading platform to distribute NASDAQ OMX price quotes including NASDAQ Basic.
Last week, Win Global Markets announced that the Company launched their mobile trading platform of www.eztrader.com on iPhone and Android smart-phones. Their customers can download the mobile application via iPhone's AppStore© and through AndroidMarket©. The advanced mobile application provides customers with the same high-end features to trade and manage their accounts as on the Internet.
Shimon Citron, CEO of Win Global Markets, commented, "We have seen a global trend of increased mobile trading volume on the advanced smart-phones. Our application delivers an advanced and dynamic trading experience designed to work on all smart-phones. It is clear that active traders look for mobility as a flexible tool which enables trading anytime and anywhere."
Win Global Markets, Inc. (WGMI), closed Thursday's trading session at $0.13, even with yesterday’s close. The average volume for the last 60 days is 8,738. The 52-week low/high is $0.05/$0.15.
Green Technology Solutions, Inc. (GTSO)
The QualityStocks Daily Newsletter would like to spotlight Green Technology Solutions, Inc. (GTSO). Today, Green Technology Solutions, Inc. closed trading at $2.95, up 1.72%, on 18,010 volume with 32 trades. The stock’s average daily volume over the past 60 days is 15,360, and its 52-week low/high is $1.02/$8.82.
Green Technology Solutions, Inc. reported today on continuing discussions with tungsten miners and prospectors amid rising demand for tungsten that places the company in prime position to turn waste into wealth by recycling this scarce, extraordinarily hard metal that is in high demand across multiple sectors via a relatively simple new thermo-mechanical process that allows tungsten alloy to be recovered from exiting products like bits and other machine parts.
Green Technology Solutions, Inc. (GTSO), via GTSO Resources, is an early-stage company poised for rapid growth by feeding the exploding demand for the versatile metal tungsten. With the demand for tungsten now far exceeding supplies, GTSO is capturing the opportunity to link with mining experts around the world, targeting tungsten mining companies for acquisition or joint venture. To date, the company has developed significant relationships with early and mid-stage mining experts and companies in the U.S., China, Africa, and South America.
Why tungsten? It's natural to think of underground wealth in terms of things like gold or silver, oil or natural gas. But the hot underground commodity today is increasingly tungsten, a heavy super-hard grey metal so versatile that it has become virtually indispensable to modern life. Second only to diamonds in terms of measured hardness, it is essential to any type of application requiring toughness, precision, and the ability to withstand heat and wear, from missile parts to armor-piercing tank shells, from drill bits and saw blades to a whole range of electrical components.
The one problem with tungsten is that there simply isn't enough of it. Demand has been growing, as more countries industrialize, but world tungsten production has actually been relatively flat. For years, the tungsten market has been dominated by China, the source of close to 90% of worldwide tungsten production. Today, as China's own growing industries demand more tungsten, they've been cutting back on exports, causing prices to soar.
The price of tungsten jumped 35% in 2011, with steep increases continuing in 2012. It's one of the reasons that Warren Buffett and Berkshire Hathaway unit IMC International Metalworking recently agreed to invest $80 million in a tungsten mining project in South Korea. Global supplies simply can't keep up with global demand. The search for new resources begins now, and GTSO Resources sees itself as leading the way. Disclaimer
Green Technology Solutions, Inc. Blog
Green Technology Solutions, Inc. News:
GTSO Explores Technology That Turns Waste into Wealth
GTSO Opens Joint Venture Talks with Alaskan Mining Company
GTSO Sends Representative to Canada to Explore Promising Tungsten Opportunities
Quantum International Corp. (QUAN)
The QualityStocks Daily Newsletter would like to spotlight Quantum International Corp. (QUAN). Today, Quantum International Corp. closed trading at $2.90, up 3.57%, on 33,810 volume with 42 trades. The stock’s average daily volume over the past 60 days is 16,792, and its 52-week low/high is $1.75/$16.50.
Quantum International Corp. (QUAN) is an emerging robotics innovation company that's setting the stage for the next generation of automation technology. The company is targeting leading-edge developers of advanced robotics technologies for acquisition or partnership, with the goal of developing and marketing these technologies to meet fast rising global demand. In particular, the company is exploring new innovations in medical robotics, adding one exploding market on top of another.
With the rapid advancement of sophisticated sensory and control electronics, the promise of economic robotic applications is finally becoming a reality. Although industrial robots have been around for a long time, smaller, lighter, and less expensive versions are finally beginning to play a serious role in the marketplace. It's much like the development of the computer, from a room-size electrical monster, costing millions, to a desktop, laptop, and now handheld electronic wizard that almost anyone can afford.
The worldwide demand for robots is growing rapidly, seen as a now affordable source of controlled energy. The global market for robots is currently estimated at $3.2 billion, with experts projecting the industry to approach $70 billion by 2025. In addition industrial applications, robots are now a crucial part of everyday life for an increasing number of individuals in their home. Personal assistance robots are helping the elderly, paralyzed, and chronically ill lead more independent lives, presenting a major breakthrough in home care with countless benefits.
Add to that the natural growth of the massive health care industry, and medical technology, and it's easy to see why, according to ABI Research, the medical robots industry is expected to reach $1.3 billion by 2016. As an example, various forms of robotic technology are already being used in hospital operating rooms to make difficult or impossible operative procedures now doable. But that same technology can be applied to many other industries, such as consumer electronics, agriculture, wind and solar, and manufacturing. Disclaimer
Quantum International Corp. Company Blog
Quantum International Corp. News:
QUAN Contacts New Robotics Targets
QUAN Works to Take Robotics Out of the Lab and Into the Marketplace
QUAN: Home Care Robots Could Transform Personal Assistance Market
Beacon Enterprise Solutions Group, Inc. (BEAC)
The QualityStocks Daily Newsletter would like to spotlight Beacon Enterprise Solutions Group, Inc. (BEAC). Today, Beacon Enterprise Solutions Group, Inc. closed trading at $0.08, up 8.70% on 72,200 volume with 10 trades. The stock’s average daily volume over the past 60 days is 69,030, and its 52-week low/high is $0.0831/$0.47.
Beacon Enterprise Solutions Group, Inc. (BEAC) specializes in designing, implementing and managing high performance Information Technology Systems ("ITS") infrastructure solutions. Offering national, multi-national and global, turnkey ITS infrastructure solutions, the company is capable of delivery professional services to Fortune 1000 and large multi-site firms as they increasingly single source and outsource to reduce costs while optimizing critical planning, design, program, project and construction management and managed services.
Leveraging standardization, rapid mobilization and a just-in-time professional services approach, Beacon Enterprise Solutions serves as a single source for national, multi-national and global enterprise clients, including special practices focused on data centers, campuses, smart buildings, outside plant, wireless systems and other technology-based applications and projects. Clients are provided with consistent and predictable results anywhere in the world. The company's solutions allow clients to focus on their core businesses without the distraction of having employees spend valuable time on services that Beacon can provide on any continent, in any country using any language.
Headquartered in Louisville, Kentucky, with regional headquarters in Cincinnati, Ohio, Dublin, Ireland, and Prague, Czech Republic, in addition to personnel located throughout the United States and Europe, Beacon Enterprise Solutions services a diverse range of clients. For more than 30 years, the company has enabled businesses in a variety of vertical markets to dramatically reduce costs, enable global standardization, manage day-to-day technology systems moves, adds and changes, and take on major projects – all under a single national, multi-national or global agreement.
Beacon Enterprise Solutions has carefully assembled a seasoned management team and operating strategy to maximize organic growth and new business development across multiple vertical markets. More than 4,000 companies, from small businesses to Fortune 50 firms, have chosen the company's solutions. Disclaimer
Beacon Enterprise Solutions Group, Inc. Blog
Beacon Enterprise Solutions Group, Inc. News:
Beacon Enterprise Solutions Reports Results for Fiscal Second Quarter 2012
Beacon Enterprise Solutions Senior Management to Make Individual Voluntary Open Market Stock Purchases
Beacon Enterprise Solutions to Host Conference Call May 2, at 10:00 a.m. EDT to Discuss Fiscal Second Quarter Results
FluoroPharma Medical, Inc. (FPMI)
The QualityStocks Daily Newsletter would like to spotlight FluoroPharma Medical, Inc. (FPMI). Today, FluoroPharma Medical, Inc. closed trading at $0.85, even with yesterday's close, on 100 volume with 1 trade. The stock’s average daily volume over the past 60 days is 26,841, and its 52-week low/high is $0.56/$2.15
FluoroPharma Medical, Inc. (FPMI) is a cutting edge provider of information, content distribution, media management and secure communications to the hospitality industry. The company's state of the art digital technology platform and Internet Protocol (IP) infrastructure presents hotels with a valuable opportunity to generate new revenue while enhancing guests' experiences by providing content that is more relevant to their unique interests.
The company's integrated platform stands far beyond the competition, offering unparalleled guest services such as messaging, folio review, express check outs, energy management and other personalized services while providing the traditional services of Free to Guest (FTG) programming, Video-On-Demand programming, a highly secured high speed internet service and many other interactive services such as gaming.
By combining TV and the web world through unparalleled IPTV/HDTV service, hotels are able to generate additional income through commercial spots, advertisements of local tourist services, hotel promotions and more. Features of the platform includes remote administration, support for more than twenty languages, easy installation and a comprehensive hotel services menu capable of providing detailed information about the hotel and upcoming activities, billing information, room service, guest messages and wake-up services.
The system's architecture consists of a Network Operating Center (NOC) and local hotel servers connected through a point-to-point broadband network. As each guest accesses the network, the resulting traffic generated undergoes analysis based on various criteria. This includes behavioral, geographical, seasonality, and more. Using this data, hotels are able to ensure advertisers maximum value for their advertising budget. Disclaimer
FluoroPharma Medical, Inc. Company Blog
FluoroPharma Medical, Inc. News:
FluoroPharma is Granted Patent Rights for BFPET in Australia, Expanding Global Patent Position
FluoroPharma Medical Announces Phase II Study for CardioPET
FluoroPharma to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
Today before the opening bell, GTSO Resources said it is exploring innovative new techniques that are making tungsten recycling more profitable and environmentally sound than ever before. The emerging mineral exploration company continues preliminary discussions with tungsten miners and prospectors, as well.
Second only to diamond, tungsten is an extraordinarily hard metal. Its unique properties make the element critical to the manufacture of a wide array of indispensable items. As demand for the metal rises worldwide and available supplies tighten, a relatively simple new thermo-mechanical process allows recyclers to break down tungsten from alloys in drill bits, machine parts, and other products to produce a high-grade powder suitable for new manufacturing uses.
“We see incredible earning potential in tungsten recycling as this unique metal becomes more and more critical to modern life,” stated GTSO CEO Paul Watson. “In addition to profit potential realized through this technology, recycling also offers a much more environmentally friendly solution than mining to increase global supplies of this invaluable metal”
“GTSO will continue to pursue advantageous new agreements and potential partnerships with the emerging leaders in tungsten mining and exploration as we explore innovative ways to recycle waste and capitalize on the mineral’s soaring global demand,” he added.
GTSO isn’t the only company pursuing new opportunities in the booming tungsten market. IMC Group, a subsidiary of Warren Buffett’s Berkshire Hathaway, recently invested $70 million in the mining company Woulfe’s South Korean tungsten operations.
For more information on GTSO Resources’ aggressive growth plans, please visit www.gtsoresources.com/investors.html
FluoroPharma, a developer of specialized molecular imaging pharmaceuticals used with positron emission tomography (PET) to help detect heart disease and other problems, has stated that it intends to develop its products through the completion of phase II and/or phase III studies, at which point it will seek to partner with organizations that may facilitate the further development and distribution of its products.
Phase I clinical trials have already been completed on the company’s two lead products, CardioPET and BFPET, with pre-clinical trials completed for VasoPET, all related to cardiovascular disease (CAD) detection. The company’s AZPET product for detecting amyloid deposits in the brain for Alzheimer’s disease evaluation is currently in the development stage. Over 12 million patients in the U.S. alone have some degree of acute or chronic CAD, and millions of patients undergo molecular imaging studies every year, often to detect and evaluate such heart disease.
Assuming CardioPET and BFPET are approved, their competition will be the current standard of care, and companies that are engaged in the development and commercialization of novel cardiac perfusion agents. However, FluoroPharma says it does not see competition coming from specific competitors for CardioPET and to some degree for BFPET. FluoroPharma’s technologies will be competing mainly on an indication-by-indication basis with the existing or coming standards of care.
FluoroPharma believes current experimental imaging agents are limited by their short half-lives (generally less than ½ hour), requiring faster image collection and/or an on-site cyclotron or generator to provide an additional supply. For this reason, they believe that these agents represent little or no potential competition to FluoroPharma products. In contrast, the imaging agent used in FluoroPharma products has a 110-minute half-life, and is more amenable to regional production and distribution to off-site nuclear medicine centers.
For more information, see the company website at www.FluoroPharma.com
Texas Gulf Energy, via its wholly-owned subsidiaries, like the company’s primary operating arm, International Plant Services (IPS), provides a broad spectrum of integrated energy services, from oil/gas production and project management, to professional consulting for both domestic and international refinery, chemical, construction, mining, and power concerns.
Chairman and CEO of TXGE, David Mathews, reported on results from operations today, in conjunction with release of the company’s full 10-Q (available on their website) for Q1, underscoring the whopping 60% increase in revenues from last year, as TXGE has pulled in some $9.1M in the first quarter of this year (largely due to increased utilization at IPS and the improved underlying market conditions). Mathews expressed the great confidence management has in the overall business model’s performance, explaining that operations have already significantly exceeded expectations.
The job they have done building this company since its inception in 2003 is indeed remarkable, bringing together a family of subsidiaries who have become widely known and trusted throughout the energy markets as providing exemplary construction capabilities and the skilled person to execute. As the company enters its tenth year of operations, things are really looking up, with the earned reputation really paying off amid continued increases in domestic hydrocarbon activity, and the company’s subsidiaries providing everything from wellhead services to consulting.
The U.S. has truly re-emerged as a frontline in the global energy resource production sector and taking a look at Q1 data coming out of TXGE, we have a good barometer of this resurgence. Comparing the figures for Q1 to the same period last year, we see:
Revenues (consolidated) – up 60% to $9.1M
Gross Profits – up 16% to 21.6%, or $1.96M on improved utilization/rates
Employee Utilization – up 19% to a very healthy 95%
Customer Rates were improved across the board, as well as Vendor Rates
Additionally, there were three large, one-time expense items associated with the acquisition of three companies by TXGE, for which the company incurred fees and non-cash compensation expenses totaling $414k. Thus, SG&A Expense (expressed as a percentage of revenue) was up roughly 9% to $1.9M, closing the quarter at around 21% (when compared to last year’s figures), due in large part to the higher operating costs associated with new units being brought online that were not yet producing (as well as certain other costs associated with becoming a fully reporting public company and other ancillary acquisitive/strategic efforts). This expense is projected by management to drop sharply as new business units bring more projects on board, with the associated revenues offsetting SG&A, in accordance with the company’s plan for 2012.
Clearly, TXGE has invested a great deal of time and effort assembling a portfolio of services companies, and made a name for itself among top industry players like Chevron, Conoco Phillips, and Exxon Mobil in the process. Results are reflected in the company’s Q1 bottom line and readily extensible as the domestic hydrocarbon area not only shows no signs of slowing down, but is in fact speeding up dramatically as new hydrocarbon resources are discovered right here at home and in emerging markets abroad as well. The company has continually sought to integrate its envelope of offerings and today stands atop an impressive foundation of some of the most skilled armies of engineering, construction, technical, skilled craft, and project management personnel anywhere.
With a guy like David Mathews at the helm, it’s not hard to see why TXGE has risen so meteorically into the skies over the Texas gulf (he took Inserv Construction Services in Houston from startup to industry powerhouse in just four years). So confident is Matthews in TXGE that he and a group of his assembled investors put $3M of their own money into the business, expressing the overwhelming confidence this industry giant has in the underlying business model. But it’s not hard to deconstruct this decision, after all the gulf region, and the domestic energy production market in general, look to have a very bright future where, if anything, a lack of such competent services/personnel to deliver them are in short supply.
For more information on this rapidly emerging energy services powerhouse, or to learn more about Texas Gulf Energy, Inc. subsidiaries, please start by visiting the company’s website at: www.TGNRG.com
Morgan Creek Energy announced that on May 14, 2012, it entered into a share exchange agreement with Glob Media Works, Inc., a Washington based social search destination company, and all of the shareholders of Glob Media. Through the Agreement, Morgan Creek expects to obtain the rights of a 100% interest in the intellectual property rights and business operations of Glob Media’s online search and social media related cloud based software application.
Pursuant to the Agreement, Glob Media and its shareholders have agreed to sell all of the issued and outstanding shares of Glob Media to Morgan Creek. The cumulative price off all purchased shares is 9,075,734 restricted shares of common stock of Morgan Creek. The shares will be distributed on a pro rata basis in accordance with each vendor’s percentage of ownership in Glob Media.
The closing of the Agreement is contingent upon the satisfaction of conditions precedent to closing as set forth in the agreement, including, but not limited to: (i) the Company, Glob Media and the Vendors having obtained all authorizations, approvals or waivers that may be necessary or desirable in connection with the transactions contemplated by the Agreement; (ii) the Company, Glob Media and the Vendors shall have complied with all warranties, representations, covenants and agreements therein agreed to be performed or caused to be performed on or before the closing date; (iii) no action or proceeding in law or in equity shall be pending or threatened by any person, company, firm, governmental authority, regulatory body or agency to enjoin or prohibit any of the transactions contemplated by the Agreement; (iv) completion by each of the Company and Glob Media of an initial due diligence and operations review of the other’s respective businesses and operations; (v) no material loss or destruction of or damage to the Company or Glob Media shall have occurred; and (vi) the board of directors of the Company and Glob Media ratifying the terms and conditions of the Agreement.
Upon the closing of the Agreement, the shares of Morgan Creek will be issued to the Vendors and will not be registered under the Securities Act of 1933, as amended, or under the securities laws of any state in the United States, and will be issued in reliance upon an exemption from registration under the Securities Act of 1933. The securities may not be offered or sold in the United States without registration under the Securities Act of 1933 or an applicable exemption from such registration requirements.
For more information, please visit www.morgancreekenergy.com
Today's Top 3
The QualityStocks Public Company Sponsor News